First, to our knowledge, it is the first prospective longitudinal study that evaluated the association between NAFLD and liver enzymes (AST, ALT, ALK-P, and GGT) with the incidence risk of CVD complications in patients with T2D, and the prospective design of this study can establish a causal relationship between the measured variables. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.